Get Live Data

The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. ARIX.L Share Price
  4. ARIX.L Share Regulatory News
  5. PDMR Notification & Director Shareholding

Pin to quick picksARIX.L Regulatory News (ARIX)

ARIX.L Information
  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PDMR Notification & Director Shareholding

2 Nov 2023 18:20

Arix Bioscience PLC (ARIX) PDMR Notification & Director Shareholding 02-Nov-2023 / 18:20 GMT/BST

Arix Bioscience plc("Company")

PDMR Notification & Director Shareholding

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

The Company has been notified that Peregrine Moncreiffe, Director and Chairman of the Company purchased 60,000 Ordinary shares of 0.001 pence each in the Company (“Shares”) on 2nd November 2023 at a price of £1.1469 per share.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Peregrine Moncreiffe

2

 

Reason for the notification

 

a)

 

Position/status

 

 Non-Executive Director and Chair of the Board

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each

Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Share purchase

c)

Price(s) and volume(s)

 

Price(s)£

Volume(s)

 

 

 

1.1469

60,000

 

 

d)

 

Aggregated information

 

- Aggregated volume

60,000

- Price

£68,815.20

e)

 

Date of the transaction

 

2 November 2023

f)

 

Place of the transaction

 

Outside a trading venue

For further information please contact: Kin Company Secretarial Limited, Company Secretary+44 20 8819 6486

Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
ISIN:GB00BD045071
Category Code:DSH
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:282417
EQS News ID:1764141
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

3456789101112
Date   Source Headline
11th Dec 20197:05 amPRNIterum announces topline Phase 3 data
9th Dec 20197:01 amPRNAutolus announces new AUTO3 data at ASH
9th Dec 20197:00 amPRNAutolus announces key new data at ASH
22nd Nov 20199:57 amPRNHolding(s) in Company
21st Nov 201912:06 pmPRNHarpoon and AbbVie announce licensing and option deal
7th Nov 201912:22 pmPRNAutolus reports Q3 2019 financial results
7th Nov 20197:22 amPRNChange of Broker
6th Nov 20192:31 pmPRNAutolus to present new data at the ASH Annual Meeting
6th Nov 20197:02 amPRNArtios expands DDR pipeline with new asset
17th Oct 20191:40 pmPRNHolding(s) in Company
16th Oct 20198:00 amPRNAura reports updated Phase 1b/2 clinical data for AU-011
15th Oct 20193:20 pmPRN]Holding(s) in Company
3rd Oct 20197:06 amPRN2019 Capital Markets Day
2nd Oct 20197:00 amPRNManagement change
30th Sep 20197:00 amPRNArix co-leads EUR 20m Series A financing in STipe
17th Sep 20197:47 amPRNAmplyx unveils expanded pipeline and Phase 2 data
28th Aug 20197:00 amPRNInterim results for the six months ended 30 June 2019
20th Aug 20197:25 amPRNNotice of Results
8th Aug 20191:03 pmPRNAutolus reports Q2 2019 financial results
1st Aug 20197:00 amPRNTotal Voting Rights
8th Jul 20193:34 pmPRNHolding(s) in Company
3rd Jul 20197:00 amPRNIssue of Ordinary Shares, TVR, PDMR Notifications
28th Jun 20193:22 pmPRNHolding(s) in Company
25th Jun 20194:17 pmPRNHolding(s) in Company
18th Jun 20195:23 pmPRNHolding(s) in Company
3rd Jun 20195:51 pmPRNCorrection: Result of AGM
3rd Jun 20195:16 pmPRNResult of AGM
3rd Jun 20197:00 amPRNTotal Voting Rights
10th May 20197:00 amPRNDirector/PDMR Shareholding
1st May 20197:00 amPRNIssue of Ordinary Shares and Total Voting Rights
16th Apr 20197:00 amPRNAutolus announces closing of public offering
11th Apr 20197:00 amPRNAutolus announces pricing of public offering
9th Apr 20197:00 amPRNAutolus announces launch of proposed public offering
2nd Apr 20197:08 amPRNAura completes $40 million Series D financing
1st Apr 20196:10 pmPRNAutolus presents initial AUTO1 data at AACR
28th Mar 20197:00 amPRNAnnual Results for the year ended 31 December 2018
28th Mar 20197:00 amPRNBoard changes
26th Mar 201910:17 amPRNAutolus hosts R&D day and provides update on AUTO3
20th Mar 201912:23 pmPRNNotice of Results
18th Mar 20197:00 amPRNArix co-leads $63m Series B investment round for Imara
19th Feb 201912:12 pmPRNAutolus announces updated results from CARPALL trial
19th Feb 20197:00 amPRNManagement and Board changes
14th Feb 20197:00 amPRNHarpoon closes initial public offering
8th Feb 20197:09 amPRNHarpoon prices Nasdaq IPO
1st Feb 201910:38 amPRNTotal Voting Rights
29th Jan 20192:25 pmPRNUpdate on Harpoon proposed IPO in the United States
3rd Jan 20197:00 amPRNIssue of Ordinary Shares and Total Voting Rights
28th Dec 20187:00 amPRNHarpoon announces proposed public offering in the US
11th Dec 20187:00 amPRNArix appoints Dr Christian Schetter as EIR
3rd Dec 20187:00 amPRNAutolus presents initial AUTO3 clinical data at ASH
3456789101112

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.